Celcuity (CELC) recently released positive results from its phase 3 VIKTORIA-1 trial, which used its drug gedatolisib in combination with other therapies to treat patients with PIK3CA wildtype ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback